(Q35981902)

11 August 2017

Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)) (English)

1 reference

11 August 2017

1 reference

Marsoni S

1

1 reference

11 August 2017

Torri V

2

1 reference

11 August 2017

Valsecchi MG

3

1 reference

11 August 2017

Belloni C

4

1 reference

11 August 2017

Bianchi U

5

1 reference

11 August 2017

Bolis G

6

1 reference

11 August 2017

Bonazzi C

7

1 reference

11 August 2017

Colombo N

8

1 reference

11 August 2017

Epis A

9

1 reference

11 August 2017

Favalli G

10

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 September 1990

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

62

1 reference

11 August 2017

3

1 reference

11 August 2017

444-450

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1990.315

11 August 2017

0 references

cites work

Controversy over combination chemotherapy in advanced ovarian cancer: what we learn from reports of matured data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

2 October 2017

Treating ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Common epithelial cancer of the ovary (2).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Randomized trial of the addition of cis-platin (DDP) and/or BCG to cyclophosphamide (CTX) chemotherapy for ovarian carcinoma.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study

24 September 2018

1 reference

12 December 2020

Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum

1 reference

12 December 2020

Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma

1 reference

12 December 2020

A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma

1 reference

12 December 2020

cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma

1 reference

12 December 2020

Ovarian carcinoma: a multivariate analysis of prognostic factors

1 reference

12 December 2020

Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial

1 reference

12 December 2020

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study

1 reference

12 December 2020

Prognostic factors in advanced ovarian carcinoma

1 reference

12 December 2020

A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer

1 reference

12 December 2020

Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment

1 reference

12 December 2020

Accrual to Clinical Trials1

1 reference

12 December 2020

Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1990.315

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

2119684

1 reference